Nocturia

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

JW PharmaceuticalKorea - Seoul

1 program

SilodosinPhase 41 trial

Active Trials

NCT02106182Completed135Est. Aug 2016

SandozAustria - Kundl

1 program

darifenacinPhase 41 trial

Active Trials

NCT01018225Withdrawn0Est. Jul 2010

Sanwa Kagaku KenkyushoJapan - Nagoya

1 program

[14C]-SK-1404Phase 11 trial

Active Trials

NCT02878096Completed6Est. Aug 2016

Ferring PharmaceuticalsArgentina - Buenos Aires

15 programs

DesmopressinN/A1 trial

SyBeMePN/A1 trial

A. Desmopressin 10 microgramPHASE_21 trial

A: Desmopressin 25 µgPHASE_21 trial

DesmopressinPHASE_21 trial

+10 more programs

Active Trials

NCT03089073Terminated835Est. Oct 2018

NCT01576900Completed124Est. Oct 2014

NCT01684800Completed178Est. Jun 2013

+12 more trials

Angeles TherapeuticsCA - Los Angeles

1 program

Integrated Behavioral Therapy ProgramN/A1 trial

Active Trials

NCT06110091Recruiting192Est. Aug 2028

NovartisBASEL, Switzerland

1 program

darifenacinPHASE_4

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

JW PharmaceuticalSilodosin

Sandozdarifenacin

Ferring PharmaceuticalsDesmopressin ODT 25 μg

Ferring PharmaceuticalsDesmopressin

Ferring PharmaceuticalsDesmopressin Melt

Ferring Pharmaceuticalsdesmopressin acetate

Ferring PharmaceuticalsFE 201836

Ferring PharmaceuticalsDesmopressin

Ferring PharmaceuticalsA. Desmopressin 10 microgram

Ferring PharmaceuticalsA: Desmopressin 25 µg

Ferring PharmaceuticalsDesmopressin

Showing 15 of 19 trials with date data

Clinical Trials (19)

Total enrollment: 5,183 patients across 19 trials

NCT02106182 JW PharmaceuticalSilodosin

Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia

Start: Jan 2014Est. completion: Aug 2016135 patients

Phase 4Completed

NCT01018225 Sandozdarifenacin

Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness

Start: Nov 2009Est. completion: Jul 20100

Phase 4Withdrawn

NCT03051009 Ferring PharmaceuticalsDesmopressin ODT 25 μg

Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Subjects

Start: Jan 2017Est. completion: Sep 2018503 patients

Phase 3Completed

NCT02904759 Ferring PharmaceuticalsDesmopressin

Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects

Start: Sep 2016Est. completion: Sep 2017342 patients

Phase 3Completed

NCT02905682 Ferring PharmaceuticalsDesmopressin

Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects

Start: Sep 2016Est. completion: Sep 2017190 patients

Phase 3Completed

NCT01552343 Ferring PharmaceuticalsDesmopressin

Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary

Start: Mar 2012Est. completion: Jun 201256 patients

Phase 3Completed

NCT01262456 Ferring PharmaceuticalsDesmopressin

Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients

Start: Feb 2011Est. completion: Jan 2012395 patients

Phase 3Completed

NCT01223937 Ferring PharmaceuticalsDesmopressin

Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients

Start: Nov 2010Est. completion: Nov 2011268 patients

Phase 3Completed

NCT00615836 Ferring PharmaceuticalsDesmopressin Melt

An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults

Start: Dec 2007Est. completion: May 2010554 patients

Phase 3Completed

NCT00477490 Ferring Pharmaceuticalsdesmopressin acetate

Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia

Start: May 2007Est. completion: Feb 2008799 patients

Phase 3Completed

NCT03201419 Ferring PharmaceuticalsFE 201836

A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults

Start: Jul 2017Est. completion: Oct 2019302 patients

Phase 2Completed

NCT01779466 Ferring PharmaceuticalsDesmopressin

Daytime Impact Sleep Study

Start: Apr 2013Est. completion: Jun 20145 patients

Phase 2Terminated

NCT01684800 Ferring PharmaceuticalsA. Desmopressin 10 microgram

Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Women

Start: Sep 2012Est. completion: Jun 2013178 patients

Phase 2Completed

NCT01694498 Ferring PharmaceuticalsA: Desmopressin 25 µg

Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Men

Start: Sep 2012Est. completion: Jun 2013183 patients

Phase 2Completed

NCT01184859 Ferring PharmaceuticalsDesmopressin

Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo

Start: Jul 2010Est. completion: Apr 2011116 patients

Phase 2Completed

NCT02878096 Sanwa Kagaku Kenkyusho[14C]-SK-1404

Bioavailability of [14C]-SK-1404 ADME & IV Microtracer Study

Start: Jul 2016Est. completion: Aug 20166 patients

Phase 1Completed

NCT06110091 Angeles TherapeuticsIntegrated Behavioral Therapy Program

Multi-center Trial to Improve Nocturia and Sleep in Older Adults

Start: Dec 2023Est. completion: Aug 2028192 patients

N/ARecruiting

NCT03089073 Ferring PharmaceuticalsDesmopressin

Study of Minirin Melt® in Adult Patients With Nocturia

Start: Jul 2015Est. completion: Oct 2018835 patients

N/ATerminated

NCT01576900 Ferring PharmaceuticalsSyBeMeP

The Effect of Combined Systematized Behavioural Modification Education Program (SyBeMeP) With DDAVP in Patients With Nocturia

Start: Apr 2012Est. completion: Oct 2014124 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 5,183 patients

6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.